Pain pumps, formally called intrathecal drug delivery systems, use a small surgically implanted device to send medication directly into the fluid surrounding the spinal cord. Only two drugs carry formal FDA approval for intrathecal pain management: morphine and ziconotide. In practice, though, clinicians draw from a wider toolkit that includes other opioids, local anesthetics, and several adjuvant agents, often combined in the same pump reservoir. The choice of medication depends on the type and severity of pain, whether the patient has cancer, and how they respond to an initial trial period.
Morphine and Ziconotide as First-Line Options
Morphine has been the backbone of intrathecal pain therapy for decades. It works the same way other opioids do, binding to receptors in the spinal cord and brain, but because it is delivered directly to spinal fluid, the doses involved are a fraction of what a patient would need by mouth or through an IV. That efficiency is the whole point of a pain pump: less drug, more relief, fewer systemic side effects like sedation or constipation. The tradeoff is that morphine delivered this way still carries risks unique to the intrathecal route, including respiratory depression, the potential for tolerance over time, and a complication called granuloma formation, where an inflammatory mass builds up at the catheter tip. Both morphine dose and concentration have been strongly linked to granuloma development.1Clinical Neurology and Neurosurgery. Intrathecal granuloma formation as result of opioid delivery: Systematic literature review of case reports and analysis against a control group
Ziconotide is the other FDA-approved intrathecal analgesic, but it is nothing like morphine. It is a synthetic version of a peptide originally found in the venom of a marine cone snail, Conus magus, and it was approved in 2004.2Heliyon. A comprehensive review on ziconotide Instead of hitting opioid receptors, ziconotide blocks N-type calcium channels in the spinal cord, which interrupts pain signaling before it reaches the brain.3PubMed Central. Ziconotide: a review of its pharmacology and use in the treatment of pain That distinction matters in several practical ways. Unlike morphine, prolonged use of ziconotide does not lead to tolerance or addiction, and it does not cause respiratory depression, which is one of the most feared complications with intrathecal opioids.4Heliyon. A comprehensive review on ziconotide Expert consensus panels have placed ziconotide alongside morphine as a first-line intrathecal agent for severe chronic pain that has not responded to other treatments.3PubMed Central. Ziconotide: a review of its pharmacology and use in the treatment of pain
Despite those advantages, ziconotide has a narrow therapeutic window. Side effects tend to show up at higher doses and include dizziness, confusion, problems with gait and balance, memory impairment, nausea, and drowsiness.5PubMed Central. Safety and efficacy of intrathecal ziconotide in the management of severe chronic pain Early clinical experience with ziconotide was rough because clinicians ramped doses up too quickly. Slower titration schedules, starting at very low doses and increasing gradually over weeks, have since made the drug far more tolerable.6Journal of Pain and Symptom Management. A Randomized, Double-Blind, Placebo-Controlled Study of Intrathecal Ziconotide in Adults with Severe Chronic Pain Even so, neuropsychiatric effects like hallucinations and mood changes remain a concern that can make ziconotide a poor fit for certain patients, while morphine’s respiratory and granuloma risks may make it less appropriate for others.7Pain Medicine. The Relationship Between the Mechanisms of Action and Safety Profiles of Intrathecal Morphine and Ziconotide: A Review of the Literature
Other Opioids in the Pump
Morphine is the only opioid with FDA approval for intrathecal use, but it is not the only opioid that goes into pain pumps. Hydromorphone and fentanyl are both used off-label and appear in consensus guidelines as reasonable alternatives or second-line choices. Hydromorphone is pharmacologically similar to morphine, and some patients tolerate it better or get better relief from it. Fentanyl, which is more fat-soluble, behaves somewhat differently in the spinal fluid and may suit patients who develop specific side effects from the other two drugs.
A practical example: peripheral edema, or swelling in the lower legs, is an uncommon but real side effect of intrathecal hydromorphone and morphine. In a case series, four out of five patients who developed lower-extremity swelling on hydromorphone or morphine had their edema resolve completely after their intrathecal medication was switched to fentanyl, with swelling going away over an average of about 50 days.8PubMed. Resolution of Intrathecal Hydromorphone or Morphine-induced Peripheral Edema by Opioid Rotation to Fentanyl: A Case Series This kind of opioid rotation, swapping one intrathecal opioid for another when side effects emerge, is common in pain pump management.
Adjuvant Medications Added to the Mix
Many patients do not get adequate relief from a single drug in their pump. This is where adjuvant agents come in: non-opioid medications added to the reservoir alongside or instead of an opioid to target pain through a different mechanism. The most common adjuvants are local anesthetics and alpha-2 adrenergic agonists.
Bupivacaine is the local anesthetic used most often in pain pumps. It numbs nerve fibers in the spinal cord, providing an additional layer of pain relief that works well alongside opioids. A three-drug combination of hydromorphone, bupivacaine, and dexamethasone (a corticosteroid) has been studied for physical and chemical stability inside implantable pumps and was found to remain stable for up to 20 days at body temperature, which is relevant for how often the pump needs to be refilled.9PubMed Central. Stability and Compatibility of an Admixture Containing Hydromorphone, Bupivacaine, and Dexamethasone in 0.9% Sodium Chloride Injection for Intrathecal Analgesia Ropivacaine, another local anesthetic, is also used, particularly in mixtures that include ziconotide.10Neuromodulation: Technology at the Neural Interface. Physicochemical Stability Study of the Morphine-Ropivacaine-Ziconotide Association in Implantable Pumps for Intrathecal Administration
Clonidine, an alpha-2 adrenergic agonist originally used for high blood pressure, is the other major adjuvant. It reduces pain signaling through pathways that are completely independent of both opioid receptors and calcium channels, making it a useful partner for either morphine or ziconotide. A retrospective study in cancer patients found that adding intrathecal clonidine actually reduced the overall burden of medication side effects, with doses in the range of 40 to 60 micrograms per day associated with roughly 50 to 75 percent fewer side effects compared to baseline.11PubMed Central. The Addition of Intrathecal Clonidine to Reduce Medication-Related Side-Effects in Cancer Pain: A Retrospective Cohort Study That finding is counterintuitive: you would expect adding another drug to increase side effects, not decrease them. The likely explanation is that clonidine allows the doses of the primary drug to be kept lower.
Baclofen for Spasticity and Pain
Baclofen holds a somewhat special place in intrathecal therapy because its primary indication is spasticity, the stiff, involuntary muscle contractions seen in conditions like multiple sclerosis, cerebral palsy, and spinal cord injuries. But animal studies have consistently shown that baclofen also has powerful pain-relieving effects at doses that do not cause significant muscle weakness, and clinical experience has confirmed that intrathecal baclofen can relieve certain types of central pain in patients who also have spasticity.12PubMed. Intrathecal Baclofen in Pain Management For patients dealing with both spasticity and chronic pain, a baclofen pump can address two problems at once.
One serious concern with intrathecal baclofen is what happens when delivery is abruptly interrupted, whether from a catheter kink, pump malfunction, or a missed refill. Baclofen withdrawal can be life-threatening, producing fever, altered mental status, dangerously high or low blood pressure, seizures, and severe rebound spasticity that develops over one to three days.13Archives of Physical Medicine and Rehabilitation. Abrupt withdrawal from intrathecal baclofen: Recognition and management of a potentially life-threatening syndrome The symptoms can mimic sepsis, meningitis, or malignant hyperthermia, leading to delayed diagnosis if emergency providers are not aware the patient has a baclofen pump.14PubMed. Intrathecal baclofen withdrawal mimicking sepsis Patients on intrathecal baclofen are generally advised to carry a medical alert card or bracelet so that emergency teams can identify the problem quickly.
Why Drug Combinations Require Stability Testing
A pain pump reservoir sits inside the body at around 37°C and may go weeks between refills. Any time two or more drugs share that reservoir, there is a question of whether they remain chemically stable together for the full refill interval, or whether one drug degrades the other. This is not a theoretical concern: ziconotide, a peptide, is particularly fragile and can lose potency when mixed with certain formulations.
When ziconotide was combined with commercially formulated baclofen, its concentration dropped to about 82 percent of its initial level within 30 days. Using powdered baclofen instead improved that to about 87 percent over the same period, giving clinicians a longer window of reliable drug potency.15PubMed. Chemical stability of admixtures combining ziconotide with baclofen during simulated intrathecal administration For triple-drug combinations involving morphine, ropivacaine, and ziconotide, stability varied depending on the specific concentration ratios: some profiles stayed stable at body temperature for up to 60 days, while others showed ziconotide degradation that would require more frequent refills to maintain analgesic effect.10Neuromodulation: Technology at the Neural Interface. Physicochemical Stability Study of the Morphine-Ropivacaine-Ziconotide Association in Implantable Pumps for Intrathecal Administration
This stability issue is one reason pain pump management involves specialty pharmacies and careful compounding. The exact concentrations, the pH of the mixed solution, and the choice of formulation ingredients all affect how long a refill stays effective. Clinicians factor this into their scheduling: a patient whose drug mixture is known to degrade faster will need more frequent office visits for refills.
The Trialing Process Before Implantation
Before committing to a permanent implant, most patients undergo a trial period to see whether intrathecal medication actually works for their particular pain. This is standard practice and has been recommended by every iteration of the Polyanalgesic Consensus Conference, the major expert panel that sets intrathecal therapy guidelines.16PubMed. Polyanalgesic Consensus Conference–2012: recommendations on trialing for intrathecal (intraspinal) drug delivery: report of an interdisciplinary expert panel Trialing typically involves a temporary catheter placed in the spinal space, through which the candidate drug is delivered for a short period, often a few days to a week. The consensus panel has published recommendations covering trialing for morphine, ziconotide, and combination therapies, including starting doses, how to titrate, what counts as success, and when a trial may be skipped.17PubMed. The Polyanalgesic Consensus Conference (PACC): Recommendations for Trialing of Intrathecal Drug Delivery Infusion Therapy
Trialing remains somewhat controversial. Not every expert agrees on what constitutes a successful trial or whether the short-term response to a temporary catheter reliably predicts how someone will do with a permanent pump over months and years. For cancer patients with limited life expectancy, some clinicians skip the trial altogether and use dosing algorithms based on the patient’s existing opioid use to calculate an appropriate starting intrathecal dose, though the prediction ranges can be quite broad.18PubMed Central. Intrathecal pain pump infusions for intractable cancer pain: an algorithm for dosing without a neuraxial trial
Cancer Pain Versus Chronic Non-Cancer Pain
The medications used in pain pumps are largely the same regardless of whether the underlying condition is cancer, but the goals, timelines, and clinical reasoning differ. For cancer patients, the primary outcome is pain relief over a shorter window, often measured at three months, reflecting the reality that many of these patients are approaching end of life and the priority is comfort. For chronic non-cancer pain, the expectations are longer-term, with outcomes measured at one year or more, and secondary goals like improved physical function, psychological health, and reduced use of oral opioids carry more weight.19PubMed. Intrathecal therapy for cancer and non-cancer pain
These different timelines also affect medication choice. Cancer patients may tolerate more aggressive opioid dosing because the concern about long-term granuloma formation or tolerance matters less when the treatment horizon is months rather than years. Non-cancer patients, who may live with their pump for a decade or more, face a longer exposure to the risks of inflammatory masses and may benefit from starting with ziconotide or adding adjuvants early to keep opioid doses low.
Pump Refill Safety
The pump reservoir needs periodic refilling, typically every one to three months depending on drug volume and flow rate. This is done in a clinic with a specialized needle that accesses a port on the pump through the skin. It sounds straightforward, but the procedure carries a specific risk called a “pocket fill,” where medication is accidentally injected into the tissue pocket around the pump rather than into the reservoir. Reports to the pump manufacturer have included hundreds of pocket fill events worldwide, including a small number of fatal outcomes.20Pain Medicine. Ultrasound-Guided Intrathecal Pump Access and Prevention of the Pocket Fill The danger depends on the drug involved: a pocket fill of concentrated opioid can cause respiratory failure as the drug absorbs into the bloodstream rapidly, while a pocket fill of baclofen means the pump reservoir is empty and withdrawal can set in.
Best practices for preventing pocket fills include maintaining steady needle pressure throughout the refill, keeping the syringe close to the body to avoid accidental dislodgement, and using the manufacturer’s template to confirm pump position and port location.21PubMed Central. Pocket Fills for Intrathecal Pump Delivery Systems: A Narrative Review Broader safety issues with intrathecal drug delivery include catheter malfunctions, surgical-site infections, dosing errors from incorrect concentration or programming, and dangerous interactions between the intrathecal drugs and whatever the patient is taking by mouth, particularly oral opioids and benzodiazepines.22PubMed. Best practices for intrathecal drug delivery for pain
Continuous Drip Versus Programmed Boluses
Modern programmable pumps can deliver medication in different patterns. The simplest is a continuous infusion at a steady rate around the clock. More sophisticated programming can deliver intermittent boluses, small bursts of medication at set intervals, with the idea that concentrating the dose into pulses might provide better pain control or fewer side effects than a constant trickle. In practice, a randomized crossover trial comparing the two delivery modes found essentially no difference in patient-reported improvement: about 38 percent of patients felt at least minimally improved with continuous infusion versus about 37 percent with bolus dosing.23Pain Medicine. Comparison of the Effects of Intermittent Boluses to Simple Continuous Infusion on Patients’ Global Perceived Effect in Intrathecal Therapy for Pain: A Randomized Double-Blind Crossover Study Some pumps also offer patient-activated bolus features, letting the patient trigger an extra dose for breakthrough pain, similar to a patient-controlled analgesia button in a hospital.
Investigational Agents on the Horizon
The list of intrathecal pain medications has grown slowly compared to other areas of pharmacology, partly because the regulatory bar for drugs injected into the spinal canal is high and partly because the patient population is relatively small. Still, researchers have identified a number of nonopioid molecules that show promise for future intrathecal use. An expert panel flagged several candidates as worthy of further research, including intrathecal gabapentin, adenosine, octreotide, and multiple conopeptides, peptides derived from cone snail venom in the same family as ziconotide but targeting different receptors.24Neuromodulation: Technology at the Neural Interface. Future Directions for Intrathecal Pain Management: A Review and Update From the Interdisciplinary Polyanalgesic Consensus Conference 2007 None of these has reached clinical approval for intrathecal pain management, but they represent a pipeline that could eventually expand the options for patients who do not respond to or cannot tolerate the current medications. The underlying trend in the field is moving toward nonopioid intrathecal agents that avoid the tolerance, respiratory depression, and granuloma problems that come with long-term opioid delivery to the spine.